Winslow Capital Management LLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 7.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,768,829 shares of the company’s stock after selling 785,042 shares during the period. Zoetis makes up approximately 2.1% of Winslow Capital Management LLC’s holdings, making the stock its 11th largest position. Winslow Capital Management LLC’s holdings in Zoetis were worth $508,076,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. LS Investment Advisors LLC increased its position in Zoetis by 25.2% in the second quarter. LS Investment Advisors LLC now owns 16,614 shares of the company’s stock worth $789,000 after buying an additional 3,349 shares in the last quarter. Oakbrook Investments LLC boosted its stake in shares of Zoetis by 120.3% in the second quarter. Oakbrook Investments LLC now owns 55,675 shares of the company’s stock worth $2,642,000 after buying an additional 30,400 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Zoetis by 3.6% in the second quarter. Daiwa Securities Group Inc. now owns 11,500 shares of the company’s stock worth $546,000 after buying an additional 400 shares during the last quarter. Shell Asset Management Co. boosted its stake in shares of Zoetis by 36.8% in the second quarter. Shell Asset Management Co. now owns 46,930 shares of the company’s stock worth $2,227,000 after buying an additional 12,614 shares during the last quarter. Finally, Boston Advisors LLC boosted its stake in shares of Zoetis by 16.4% in the second quarter. Boston Advisors LLC now owns 71,890 shares of the company’s stock worth $3,412,000 after buying an additional 10,150 shares during the last quarter. 93.49% of the stock is currently owned by institutional investors.
Zoetis Inc. (NYSE:ZTS) traded up 0.50% during midday trading on Wednesday, hitting $54.05. The stock had a trading volume of 226,681 shares. The firm has a 50-day moving average of $52.97 and a 200-day moving average of $51.16. Zoetis Inc. has a 12-month low of $38.26 and a 12-month high of $54.72. The company has a market cap of $26.69 billion, a PE ratio of 38.97 and a beta of 1.07.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.06. The company earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.22 billion. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. Zoetis’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.50 EPS. Equities research analysts forecast that Zoetis Inc. will post $1.94 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 1st. Investors of record on Friday, January 20th will be issued a $0.105 dividend. This is a boost from Zoetis’s previous quarterly dividend of $0.10. The ex-dividend date of this dividend is Wednesday, January 18th. This represents a $0.42 dividend on an annualized basis and a yield of 0.78%. Zoetis’s dividend payout ratio is presently 30.44%.
A number of analysts have commented on ZTS shares. Bank of America Corporation started coverage on Zoetis in a research report on Thursday, September 29th. They issued a “buy” rating and a $60.00 price target for the company. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a research report on Thursday, October 6th. Stifel Nicolaus restated a “buy” rating and issued a $58.00 price target on shares of Zoetis in a research report on Wednesday, October 12th. Jefferies Group LLC restated a “buy” rating and issued a $63.00 price target on shares of Zoetis in a research report on Sunday, October 16th. Finally, J P Morgan Chase & Co restated a “hold” rating and issued a $53.00 price target on shares of Zoetis in a research report on Thursday, November 3rd. Three investment analysts have rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $57.67.
In related news, insider Roxanne Lagano sold 9,797 shares of the company’s stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $50.43, for a total value of $494,062.71. Following the completion of the transaction, the insider now owns 8,063 shares of the company’s stock, valued at approximately $406,617.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kristin C. Peck sold 10,092 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $49.55, for a total value of $500,058.60. Following the completion of the transaction, the insider now directly owns 22,768 shares of the company’s stock, valued at approximately $1,128,154.40. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).